Profile of hypertensive patients at the start of the Pharmaceutical Care.

<p>Profile of hypertensive patients at the start of the Pharmaceutical Care.</p

Example of adjustment model of data elaborated in this study to analyze the antihypertensive drugs, therapeutic doses for comparison (TDC model).

<p>Example of adjustment model of data elaborated in this study to analyze the antihypertensive drugs, therapeutic doses for comparison (TDC model).</p

Summary of measures and dispersion on consultation and consumption of antihypertensive drugs for the three periods of analysis of the results.

<p>Summary of measures and dispersion on consultation and consumption of antihypertensive drugs for the three periods of analysis of the results.</p

Percentage of average annual coronary risk calculated by the Framingham Risk Scale over the seven year follow-up of hypertensive patients.

<p>* p value <0.05 compared with the 2008 year.</p

Distribution of clinical variables over seven years of follow-up of hypertensive patients considering the 5–95 percentile range.

<p>Considering the 5–95 percentile range for distribution; LDL = Low Density Lipoprotein; HDL = High Density Lipoprotein</p

Proportion of patients with satisfactory outcomes for the three periods of analysis of the results.

<p>Proportion of patients with satisfactory outcomes for the three periods of analysis of the results.</p

Flowchart of the stratified sample size for each variable analyzed.

<p>AD = Antihypertensive Drug; PHS = Public Health System; LDL = Low Density Lipoprotein; HDL = High Density Lipoprotein.</p